Overall rank by patents
#6,606
Across all tracked assignees
USPTO PatentsView assignee record - 51 granted patents across 9 technology areas, active 2016–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Viiv holds 51 US patents across 9 technology areas, rank #6,606 of 50,000 tracked assignees.
Viiv Healthcare UK (no.5) Limited has been granted 51 US utility patents between 2016 and 2024, placing Viiv Healthcare UK (no.5) Limited at rank #6,606 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Viiv Healthcare UK (no.5) Limited is one of the more focused assignees in the PatentsView dataset. By volume, Viiv sits between Tower Manufacturing Corp. (51 patents, rank #6,602) and Yoshino Gypsum Co., Ltd. (51 patents, rank #6,610) - the closest US assignees by grant volume. The composite Innovation Score of 34.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 14 grants, compared with 37 in the 2015–2019 window, a -62% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Viiv Healthcare UK (no.5) Limited's 11.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Viiv Healthcare UK (no.5) Limited against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Tower Manufacturing Corp.
51 patents
UNIVERSITY OF LEICESTER
51 patents
VTV THERAPEUTICS LLC
51 patents
Vestel Elektronik Sanayi ve Ticaret A. S.
51 patents
WALDEMAR LINK GmbH & Co. KG
51 patents
WAPP TECH CORP.
51 patents
Xenon Pharmaceuticals Inc.
51 patents
YOSHINO GYPSUM CO., LTD.
51 patents
ViiV Healthcare UK (No.5) Limited
51 patents
What this shows Viiv holds 51 patents at rank #6,606, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,606 in granted patent volume.
Other assignees with the most granted patents in Viiv's primary technology class.
Viiv's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 51% higher than 49% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 3 | 5.9% |
| 2017 | 8 | 15.7% |
| 2018 | 15 | 29.4% |
| 2019 | 11 | 21.6% |
| 2020 | 2 | 3.9% |
| 2021 | 3 | 5.9% |
| 2022 | 3 | 5.9% |
| 2023 | 1 | 2.0% |
| 2024 | 5 | 9.8% |
Top 9 of 9 technology areas
Overall rank by patents
#6,606
Across all tracked assignees
34.8 out of 100
How to use this portfolio
Viiv's 51 grants land it in the top 51% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.